RESUMEN
OBJECTIVE: Bisphosphonate, a typical bone resorption inhibitor, is an important first-line drug for treating osteoporosis. Recent studies show a novel paradigm in stimulating bone formation. Teriparatide, which is composed of recombinant human parathyroid hormone, stimulates osteoblasts and induces bone regeneration. Bone mineral density (BMD) that was used before and after the treatment with anti-osteoporosis drug was compared for the effectiveness in therapy between a combination of teriparatide and selective estrogen receptor modulator (SERM), and bisphosphonate. METHODS: We retrospectively reviewed the outcomes of 85 postmenopausal women who were concurrently diagnosed with osteoporosis and spinal compression fracture between November 2008 and January 2015. The targeted group were treated with teriparatide and SERM (TS group, n=26) and bisphosphonate (B group, n=59). RESULTS: In both groups, BMD of femur neck was not improved after the medication. In the TS group, on the other hand the BMD and T-score of lumbar spine has significantly improved. BMD ratio of lumbar spine was prominently higher than those of TS group. CONCLUSION: The combination therapy of teriparatide and SERM was very effective in treating the lumbar spine, compared to that of bisphosphonate. Although the period of teriparatide treatment has been relatively short, the preventive effects of compression fracture were considerable. Thus, combination therapy of teriparatide and SERM is highly recommended for patients who are concerned with spinal compression fracture from osteoporosis.
Asunto(s)
Femenino , Humanos , Densidad Ósea , Regeneración Ósea , Resorción Ósea , Cuello Femoral , Fracturas por Compresión , Mano , Osteoblastos , Osteogénesis , Osteoporosis , Hormona Paratiroidea , Posmenopausia , Clorhidrato de Raloxifeno , Estudios Retrospectivos , Moduladores Selectivos de los Receptores de Estrógeno , Columna Vertebral , TeriparatidoRESUMEN
Posterior fossa is a site next to the middle fossa where arachnoid cyst frequently occurs. Generally, most arachnoid cysts are asymptomatic and are found incidentally in most cases. Although arachnoid cysts are benign and asymptomatic lesions, patients with posterior fossa arachnoid cysts often complain of headaches, gait disturbance, and ataxia due to the local mass effects on the cerebellum. We observed a patient with a posterior fossa arachnoid cyst who had visual symptoms and a headache, but did not have gait disturbance and ataxia. We recommended an emergency operation for decompression, but the patient refused for personal reasons. After 7 days, the patient revisited our hospital in a state of near-blindness. We suspected that the arachnoid cyst induced the hydrocephalus and thereby the enlarged third ventricle directly compressed optic nerves. Compressed optic nerves were rapidly aggravated during the critical seven days; consequently, the patient's vision was damaged despite the operation. Considering the results of our case, it is important to keep in mind that the aggravation of symptoms cannot be predicted; therefore, symptomatic arachnoid cysts should be treated without undue delay.
Asunto(s)
Humanos , Quistes Aracnoideos , Aracnoides , Ataxia , Cerebelo , Descompresión , Urgencias Médicas , Marcha , Cefalea , Hidrocefalia , Nervio Óptico , Papiledema , Tercer VentrículoRESUMEN
BACKGROUND: Brain metastasis is a common complication in cancer patients. We evaluated the clinical characteristics, treatment outcome and prognostic factors for patients with metastatic brain tumor. METHODS: The records of 97 patients with metastatic brain tumor during the period from January 1991 to November 1997 were reviewed retrospectively. RESULTS: The most common primary tumor is lung cancer (61 cases, 63%) followed by metastatic cancer unknown primary site (15 cases, 16%), gastrointestinal cancer (13 cases, 13%), breast cancer (6 cases, 6%) and renal cancer (2 cases, 2%). There were 44 patients with a single brain metastasis and 53 patients with multiple brain metastases. The median survival was 3.0 months and one-year survival rate was 8% irrespective of treatment. Favorable prognostic factors which affect survival were ambulatory status (p<0.01) and functional neurologic class 1, 2 (p<0.01). Median survival was 3.7 months for patients with steroid therapy and 1.1 months with no therapy (p<0.01). Median survival was 4.8 months for patients with steroid therapy plus whole brain radiotherapy (WBRT) and 2.2 months with steroid therapy alone (p<0.01). Additional chemotherapy did not appear to affect the survival. The patients treated with surgery had median survival time of 8.8 months compared with 2.5 months for patients treated with steroid therapy plus WBRT (p<0.05). CONCLUSION: In present study, we confirmed that whole brain irradiation and corticosteroid administration are effective palliative treatment for patients with metastatic brain tumor. Initial performance status and neurological function were identified as important prognostic factors. Although confounded by the limitations of retrospective study, more aggressive treatments including surgery and chemotherapy could be regarded to have a significant role to achieve better treatment outcome in some selected cases.
Asunto(s)
Humanos , Neoplasias Encefálicas , Encéfalo , Neoplasias de la Mama , Quimioterapia , Neoplasias Gastrointestinales , Neoplasias Renales , Neoplasias Pulmonares , Metástasis de la Neoplasia , Cuidados Paliativos , Pronóstico , Radioterapia , Estudios Retrospectivos , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
BACKGROUND: Pleural effusion is a common clinical problem and many clinical and laboratory evaluations, such as tumor marks, have been studied to discriminate malignant pleural fluid from benign pleural fluid. However their usefulness in the diagnosis of pleural effusion is still not established fully. We studied the diagnostic value of cyfra 21-1 in diagnosis of malignant pleural effusion. METHODS: Pleural fluid was obtained from 45 patients with malignant diseases(32 lung cancer patients, 13 metastatic malignant diseases) and 47 patients with benign diseases. The level of cyfra 21-1 in the pleural fluid and serum were determined using a CYFRA 21-1 enzyme immunoassay kit(Cis-Bio International Co.). The t-test was used for comparison between two diseases groups and receiver operating characteristic(ROC) curves were constructed by calculating the sensitivities and specificities of the cyfra 21-1 at several points to determine the diagnostic accuracy of the cyfra 21-1. RESULTS: In patients with primary lung cancer, the level of cyfra 21-1 in the pleural fluid was significantly higher than those of patients with benign diseases and had positive correlations between the level of cyfra 21-1 in the pleural fluid and serum levels. In the ROC curve analysis of the pleural fluid, the curve for primary lung cancer group was located closer to the left upper corner and the cut off value, sensitivity and specificity of the cyfra 21-1 of the primary lung cancer group was determined as 22.25ng/ml, 81.8% and 78.7% respectively. CONCLUSIONS: Our data indicates that the measurement of cyfra 21-1 level in pleural effusion has useful diagnostic value to discriminate malignant pleural effusion in primary lung cancer from benign pleural effusion.
Asunto(s)
Humanos , Diagnóstico , Diagnóstico Diferencial , Técnicas para Inmunoenzimas , Neoplasias Pulmonares , Derrame Pleural , Derrame Pleural Maligno , Curva ROCRESUMEN
BACKGROUND: Neural control of airway function is through parasympathetic, sympathetic and non-adrenergic, non-cholinergic mechanisms. The autonomic nervous system controls the airway smooth muscle tone, mucociliary system, permeability and blood flow in the bronchial circulation and release of mediators from the mast cells and other inflammatory cells. The cardiovascular and respiratory autonomic efferent fibers have a common central origin, so altered cardiovascular autonomic reflexes could reflect the altered respiratory autonomic status. Therefore, we performed this study to assess the autonomic abnormality and determine the correlating factors of severity of autonomic neuropathy in patients with chronic obstructive pulmonary disease(COPD) using easily reproducible cardiovascular autonomic reflex function test. METHOD: The study included 20 patients with COPD and 20 healthy persons obtained on Health Promotion Center in Yeungnam university hospital. All the patients had history and clinical features of COPD as defined by the American Thoracic Society. Any patients with myocardial ischemia, cardiac arrythmia, hypertension, central or peripheral nervous system disease, diabetes mellitus, or any other diseases known to produce autonomic neuropathy, has excluded. The autonomic nervous system function tests included three tests evaluating the parasympathetic system and two tests evaluating the sympathetic system. And also all subjects were subjected to pulmonary function test and arterial blood gas analysis. RESULTS: 1) Autonomic dysfunction was more commonly associated with patients with COPD than healthy person. 2) The parasympathetic dysfunction was frequent in patient with COPD, but sympathetic dysfunction seemed preserved. 3) The severity of parasympathetic dysfunction in patients with COPD was correlated with the degree of duration of disease, smoking, FEV1, FVC, and arterial hypoxemia but no such correlation existed for age, type of COPD, FEV1/FVC, or PaCO2. CONCLUSION: There is high frequency of parasympathetic dysfunction associated with COPD and the parasympathetic abnormality in COPD is increased in proportion to severity of airway disease. In COPD, parasympathetic dysfunction probably does not the cause of disease, but it may be an effect of disease progression.
Asunto(s)
Humanos , Hipoxia , Arritmias Cardíacas , Sistema Nervioso Autónomo , Análisis de los Gases de la Sangre , Diabetes Mellitus , Progresión de la Enfermedad , Promoción de la Salud , Hipertensión , Enfermedades Pulmonares Obstructivas , Mastocitos , Músculo Liso , Isquemia Miocárdica , Enfermedades del Sistema Nervioso Periférico , Permeabilidad , Enfermedad Pulmonar Obstructiva Crónica , Reflejo , Pruebas de Función Respiratoria , Humo , FumarRESUMEN
BACKGROUND: Nocturnal hypoxemia occurs in patients with chronic obstructive pulmonary disease(COPD) and the detection and treatment of nocturnal hypoxemia should be part of the management of COPD patients. We performed this study to evaluate the factors influencing to sleep related arterial oxygen desaturation(SaO2) in patients with COPD. METHODS: Resting and exercise cardiopulmonary function test, polysomnography, and SaO2 during resting, exercise and sleep were measured in 12 patients with COPD. RESULTS: The SaO2 fell twice as much during sleep as during maximal exercise(13.1 9.3% fall in nocturnal SaO2 vs. 6.4 3.3%, p<0.05). Fall in nocturnal SaO2 was well correlated with mean exercise SaO2(r=-0.78, p<0.05), minimum exercise SaO2(r=-0.90, p<0.01), and resting SaO2(r=-0.82, p<0.05). Lowest sleep SaO2 was well correlated with mean exercise SaO2(r=0.80, p<0.05), lowest exercise SaO2(r=0.90, p<0.01), and resting SaO2(r=0.84, p<0.05). CONCLUSION: Resting and exercise SaO2 was well correlated with nocturnal SaO2, but exercise study add no additional information to predicting the nocturnal oxygen desaturation in patients with COPD.
Asunto(s)
Humanos , Hipoxia , Oxígeno , Polisomnografía , Enfermedad Pulmonar Obstructiva CrónicaRESUMEN
BACKGROUND: Nearly 10% of cancer patients will develop a second primary cancer within ten years after surgical removal of the primary tumor. The detection of risk factors for developing multiple primary tumors would be important. This study was conducted to evaluate the clinical characteristics and abnormal p53 expression of lung cancer associated with multiple primary cancer(MPC). METHOD: Clinical characteristics and abnormal p53 expression were compared between 20 cases of lung cancer(NSCLC; 16 cases, SCLC; 4 cases) associated with MPC and 26 cases of primary non-small cell lung cancer. RESULT: MPC associated with lung cancer was gastric cancer(8), lung cancer(2), esophageal cancer(2), colon cancer(2), laryngeal cancer(1), bladder cancer(1), small bowel cancer(1), adrenal cancer(1), hepatocellular carcinoma(1), and breast cancer(1), in order. The clinical stage of primary NSCLC was relatively advanced, but NSCLC associated with MPC was even distribution at each stage. The detected incidences of abnormal p53 expressions were 62.5% in NSCLC associated with MPC and 76.9% in primary NSCLC(p>0.05). CONCLUSION: There was no difference in abnormal p53 expression between non-small cell carcinoma associated with multiple primary cancer and primary non-small cell carcinoma.
Asunto(s)
Humanos , Mama , Carcinoma de Pulmón de Células no Pequeñas , Colon , Incidencia , Neoplasias Pulmonares , Pulmón , Neoplasias Primarias Secundarias , Factores de Riesgo , Vejiga UrinariaRESUMEN
BACKGROUND: Because of the widespread use and availability of agricultural insecticides, acute organophosphate poisoning as a suicide or an accident is becoming the most common type of poisoning and serious problem in Korea. The mortality of organophosphate poisoning varied from 10 to 86 percent. The cause of death was thought to be a combination of excessive bronchial secretion, bronchospasm, respiratory muscle paralysis and depression of respiratory center, summarily respiratory failure. We evaluated the respiratory complications in patients with acute organophosphate intoxication to determine the predisposing factors to respiratory failure and to reduce the incidence of respiratory failure or mortality. METHOD: We conducted a retrospective study of 111 patients with the discharge diagnosis of organophosphate poisoning who were hospitalized at Yenugnam University Hospital during the 5 years. The diagnosis of organophosphate poisoning has based on the followings (1) a history of exposure to an organophosphate compounds. (2) the characteristic clinical signs and symptoms. (3)decrease in the cholinesterase activity in the serum. RESULTS: The results were as follows 1) Respiratory failure developed in 31(28%) of 111 patients with acute organophosphate poisoning. All cases of respiratory failure developed within 96 hours after poisoning and within 24 hours in 23 patients. 2) The 80 patients who did not develop respiratory failure survived. In 31 patients with respiratory failure, 15(44%) patients were dead. 3) The patients with respiratory failure had more severe poisoning, that is, the lower level of serum cholinesterase activity on arrival, the higher mean dosage of atropine administered within first 24 hours. 4) In 16 patients with pneumonia, 14 patients developed respiratory failure. In 5 patients with cardiovascular collapse, 2 patients developed respiratory failure. 5) There was no correlation to between age, sex, the use of pralidoxime and respiratory failure. 6) The serum cholinesterase level in survivors at time of respiratory failure and weaning was 66.05+/-85.48U/L, 441+/-167.49U/L, respectively. CONCLUSION: All the respiratory failure complications of acute organophosphate poisoning occurred during the first 96 hours after exposure. The severity of poisoning and pneumonia were the predisposing factors to respiratory failure. Aggressive treatment and prevention of the above factors will reduce the incidence of respiratory failure.
Asunto(s)
Humanos , Atropina , Espasmo Bronquial , Causalidad , Causas de Muerte , Colinesterasas , Depresión , Diagnóstico , Incidencia , Insecticidas , Corea (Geográfico) , Mortalidad , Intoxicación por Organofosfatos , Neumonía , Intoxicación , Centro Respiratorio , Insuficiencia Respiratoria , Parálisis Respiratoria , Estudios Retrospectivos , Suicidio , Sobrevivientes , DesteteRESUMEN
BACKGROUND: Sleep apnea syndrome, which occurs in 1-4% of the adult population, frequently has different cardiovascular complications such as hypertension, ischemic heart disease, cardiac arrythmia as well as sleep-wake disorder such as excessive daytime hypersomnolence or insomnia. Mortality and vascular morbidity are reported to be significantly higher in sleep apnea syndrome patients than in normal population. According to the recent studies, autonomic dysfunction as well as hypoxemia, hypercapneic acidosis, and increased respiratory effort, may play a role in the high prevalence of cardiovascular complications in patients with sleep apnea syndrome. However the cause and mechanism of autonomic neuropathy in patients with sleep apnea syndrome are not well understood. We studied the existence of autonomic neuropathy in patients with sleep apnea syndrome and factors which influence the pathogenesis of autonomic neuropathy. METHOD: We used the cardiovascular autonomic neuropathy(CAN) test as a method for evaluation of autonomic neuropathy. The subjects of this study were 20 patients who diagnosed sleep apnea syndrome by polysomnography and 15 persons who were normal by polysomnography. RESULTS: Body mass index and resting systolic blood pressure were higher in sleep apnea group than control group. Apnea index(AI), respiratory disturbance index(RDI) and snoring time percentage were significanfly higher in sleep apnea group compared with control group. But there were no significant differences in saturation of oxygen and sleep efficiency in two groups. In the cardiac autonomic neuropathy test, the valsalva ratio was significantly low in sleep apnea group compared with control group but other tests had no differences between two groups. The CAN scores and corrected QT(QTc) interval were calculated significantly higher in sleep apnea group, but there were no significant correlations between CAN scores and QTc intervaL There were no significant data of polysomnography to correlate to the CAN score. It meant that the autonomic neuropathy in patients with sleep apnea was affected by other multiple factors. CONCLUSION: The cardiovascular autonomic neuropathy test was a useful method for the evaluation of autonomic neuropathy in patients with sleep apnea syndrome and abnormalities of cardiovascular autonomic neuropathy were observed in patients with sleep apnea syndrome. However, we failed to define the factors that influence the pathogenesis of autonomic neuropathy of sleep apnea syndrome. This study warrants futher investigations in order to define the pathogenesis of autonomic neuropathy in patients with sleep apnea syndrome.
Asunto(s)
Adulto , Humanos , Acidosis , Hipoxia , Apnea , Arritmias Cardíacas , Presión Sanguínea , Índice de Masa Corporal , Trastornos de Somnolencia Excesiva , Hipertensión , Mortalidad , Isquemia Miocárdica , Oxígeno , Polisomnografía , Prevalencia , Síndromes de la Apnea del Sueño , Trastornos del Inicio y del Mantenimiento del Sueño , RonquidoRESUMEN
Sparfloxacin is a new synthetic quinolone antimicrobial developed at the Research Laboratories of Dainippon Pharmaceutical Co, Ltd. To evaluate the efficacy and safty of sparfloxacin in acute pulmonary infection, we administered sparfloxacina(100mg) twice in a day to 30 patients who had sign and symptoms of acute pulmonary infectious diseases regardless of their underlying lung disease for 7 days. The results were : 1) A total 30 patients were enrolled in the trial. Among them 24 cases(80%) had underlying lung problems such as chronic obstructive pulmonary disease(36.4%), bronchiectasis(36.4%), bronchial asthma(3.3%), lung cancer(3.3%). 2) In 26 cases(86.6%), we observed effective improvement, and 4 cases(13.4%) show mildly effective improvement of symptoms and signs of respiratory infection. 3) In 23 cases(73.4%), we observed bacteriological eradication in culture or decreased the number of bacteria in Gram stain which found dominantly in previous Gram stain. 4) The significant side effect was not noted. The above results suggest that sparfloxacin was effective as a first line therapy in patients with acute respiratory infection.
Asunto(s)
Humanos , Bacterias , Enfermedades Transmisibles , Pulmón , Enfermedades PulmonaresRESUMEN
To evaluate the efficacy and safety of clarithromycin in acute exacerbation of chronic obstructive pulmonary disease, we administered clarithromycin(250mg) twice in a day in 30 patients with acute exacerbation of chronic obstructive pulmonary disease from September to November in 1996. Twenty eight eases of 30 patients were cured(93.4%) and 2 cases(6.7%) show clinical improvement. Three cases were improved within 3 days of treatment and 24 cases were improved between 5 days and 12 days of treatment. There were no significant side effects. These results suggest that clarithromycin will be effective as a first line therapy in patients with acute exacerbation of chronic obstructive pulmonary disease.